Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC

Cancer-associated fibroblasts (CAFs), as crucial stromal components in the tumor microenvironment, promote tumor progression and impair responses to immunotherapy. However, targeted therapies against CAFs remain limited in HPV-negative head and neck squamous cell carcinoma (HPV - HNSCC). Here, integrated analysis of single-cell RNA sequencing (scRNA-seq), bulk RNA sequencing, ChIP sequencing, and spatial transcriptomic data identified a candidate epigenetic fibroblast target. We revealed that SET and MYND domain-containing 3 (SMYD3) played a critical role in the transformation of fibroblasts into myofibroblasts. It promoted collagen production to impair infiltration of CD8 + T cells and upregulated THBS2 in CAFs to induce M2‑like macrophage polarization. Functional studies confirmed that targeting SMYD3 not only improved the immune environment but also enhanced the efficacy of anti‑PD‑L1 therapy in vivo. Our findings established SMYD3 as a central mediator of CAF-dependent immune suppression and nominated its inhibition as a promising strategy to improve immunotherapy outcomes in HPV - HNSCC.

Authors

Institutions

Publication Details

Journal
npj Precision Oncology
Published
2026-11-19
DOI
https://doi.org/10.1038/s41698-026-01779-2
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC

Jun-yao Wu, Xiaomeng Song, Yujia Guo, Yang Yang et al.
2 links
npj Precision Oncology
Cancer Immunotherapy and Biomarkers
article

Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC

Jun-yao Wu, Xiaomeng Song, Yujia Guo, Yang Yang, Jia-Hao Zhao, Yue-Han Li, Ran Zhao, Jing-Jing Cui, Meng-Ran Zhao, An Song, Peng Lin
article en

Abstract

Cancer-associated fibroblasts (CAFs), as crucial stromal components in the tumor microenvironment, promote tumor progression and impair responses to immunotherapy. However, targeted therapies against CAFs remain limited in HPV-negative head and neck squamous cell carcinoma (HPV - HNSCC). Here, integrated analysis of single-cell RNA sequencing (scRNA-seq), bulk RNA sequencing, ChIP sequencing, and spatial transcriptomic data identified a candidate epigenetic fibroblast target. We revealed that SET and MYND domain-containing 3 (SMYD3) played a critical role in the transformation of fibroblasts into myofibroblasts. It promoted collagen production to impair infiltration of CD8 + T cells and upregulated THBS2 in CAFs to induce M2‑like macrophage polarization. Functional studies confirmed that targeting SMYD3 not only improved the immune environment but also enhanced the efficacy of anti‑PD‑L1 therapy in vivo. Our findings established SMYD3 as a central mediator of CAF-dependent immune suppression and nominated its inhibition as a promising strategy to improve immunotherapy outcomes in HPV - HNSCC.

npj Precision Oncology
Nanjing Medical University (CN)
National Natural Science Foundation of China, China Postdoctoral Science Foundation, Nanjing Medical University
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon